Current Pending Patents on Nicardipine Formulations
No patents are currently pending specifically for new formulations of nicardipine, based on the latest data from DrugPatentWatch.com. Nicardipine, a calcium channel blocker used for hypertension and angina, has several approved patents tied to its existing formulations like Cardene IV and generics, but none in pending status for novel delivery systems, extended-release versions, or other innovations as of the most recent updates.[1]
Recently Expired or Active Patents
Key patents for nicardipine hydrochloride formulations, such as those covering injectable emulsions (e.g., U.S. Patent 8,586,099 for Cardene IV), expired in 2020-2022, opening the market to generics. No new filings appear in the pipeline for reformulations like oral extended-release or liposomal versions.[1]
Who Holds Nicardipine Patents
Eisai (formerly Eisai R&D Management) owns the primary patents on nicardipine products like Cardene. Generic competitors including Amphastar Pharmaceuticals and Fresenius Kabi have ANDA approvals but no pending patent challenges or new formulation IP listed.[1]
Biosimilars or New Formulation Competitors
No biosimilars exist for nicardipine as it's a small-molecule drug, not a biologic. Recent FDA approvals focus on generic injectables rather than innovative formulations. Companies like Baxter and Pfizer have generic versions, with no Paragraph IV challenges indicating pending patent disputes for new forms.[1]
When Could New Patents Emerge
Pipeline scans show no pre-clinical or Phase I/II trials linked to nicardipine reformulations that would trigger patent applications soon. Watch for orphan drug or 505(b)(2) pathways if hypertension combos advance, but nothing is filed.[1]
[1] DrugPatentWatch.com - Nicardipine Patents